Drug intelligence / Profile preview

PulmALLO

Development stage: Unknown
Lead developer: BioCardia
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

PulmALLO (BCDA-04) is an allogeneic mesenchymal stem cell (MSC) therapy developed by BioCardia Lifesciences for the treatment of Acute Respiratory Distress Syndrome (ARDS). The therapy utilizes MSCs that are selected for the expression of the Neurokinin-1 receptor (NK-1R), the primary receptor for the neuropeptide Substance P, which plays a significant role in inflammatory signaling and tissue repair. By delivering these NK-1R-positive cells, the therapy aims to modulate the hyper-inflammatory environment characteristic of ARDS and promote lung tissue regeneration. PulmALLO is currently being evaluated in a Phase 1 clinical trial (NCT05491681) to assess safety and preliminary efficacy in patients with ARDS.

Brand names: PulmALLO

Targets

TACR1 (Neurokinin‑1 Receptor)

Beyond the preview

Go deeper on PulmALLO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PulmALLO.

Explore the full profile